Huizinga Robert Bindert 4
4 · Aurinia Pharmaceuticals Inc. · Filed Sep 8, 2021
Insider Transaction Report
Form 4
Huizinga Robert Bindert
EVP of Research
Transactions
- Sale
Common Stock
2021-09-07$18.30/sh−5,000$91,500→ 138,592 total
Footnotes (2)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 27, 2021.
- [F2]The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $18.30 to $18.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.